Anaptys Partner Search Boosted By Phase III Skin Disease Success

After disappointments in other indications, notably hidradenitis suppurativa, AnaptysBio has posted positive Phase III results for its IL-36 receptor-targeting monoclonal antibody imsidolimab in generalized pustular psoriasis.

Daniel Faga
CEO Daniel Faga • Source: AnaptysBio

AnaptysBio, Inc. has suffered a series of setbacks in the clinic with imsidolimab but its success in a late-stage trial for a rare but potentially life-threatening form of psoriasis could, it hopes, lead to a lucrative licensing deal. 

Key Takeaways
  • AnaptysBio's imsidolimab will be filed next year for generalized pustular psoriasis

The San Diego, CA-based firm has unveiled positive topline data from the Phase III GEMINI-1 trial evaluating imsidolimab in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapy Areas

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.